Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 10 clients • 16 examiners • 9 art units • 0 of 17 (0%) have an AI response strategy ready
Milstein Zhang & Wu LLC is a patent law firm focusing on Biotechnology & Pharmaceuticals. The firm has managed 983 career applications, resulting in a resolved allowance rate of 82.88 percent. Prosecution at the firm averages 3.81 office actions per allowance.
The firm currently manages 14 pending office actions. The 3.81 average office actions per allowance reflects the complexity of the Biotechnology & Pharmaceuticals sector, where multiple rounds of negotiation are often required. This data is based on 983 career applications, providing a solid foundation for performance analysis.
The 82.88 percent allowance rate shows a consistent ability to secure patent grants in a challenging field. Practitioners can use the 3.81 average office actions per allowance to set expectations for prosecution duration. The 14 pending office actions represent the firm's current active workload in this technology area.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 2 (12%) |
| §112 only | 5 (29%) |
| Double-patenting + other | 2 (12%) |
| Multi-statute (no §101) | 7 (41%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARSKY, JARED | 2 | 50.2% | +22.7% |
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.8% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| KRIANGCHAIVECH, KETTIP | 1 | 19.3% | +28.7% |
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18219656 | COMPOSITIONS AND METHODS OF DETECTING AND TREATING THROMBOSIS AND VASCULAR PLAQUES | VU, JAKE MINH | 154d overdue |
| 18387769 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | BOECKELMAN, JACOB A | 5d overdue |
| 17777363 | COMPOSITIONS AND METHODS FOR OPTOGENETIC IMMUNOTHERAPY | SUNSHINE, HANNAH LOUISE | 5d overdue |
| 18081604 | NANODEVICES AND METHODS FOR MEASURING BIOFLUIDIC FLOW USING A GRAPHENE-BASED MICROELECTRODE | MONTGOMERY, MELISSA JO | 9d |
| 18279931 | PHOTOCAGED CITRULLINE ANALOGS AND METHODS FOR SITE-SPECIFIC INCORPORATION OF CITRULLINE INTO PROTEINS | REYNOLDS, FRED H | 57d |
| 18904564 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | BRAUN, MADELINE E | — |
| 18528393 | PROTEIN KINETIC ENSEMBLE PLATFORM FOR DISCOVERY OF BINDING POCKETS AND NOVEL LIGANDS | KRIANGCHAIVECH, KETTIP | — |
| 18277846 | Novel Compositions for Conjugating Oligonucleotides and Carbohydrates | VANHORN, ABIGAIL LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18387769 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | BOECKELMAN, JACOB A | 5d overdue |
| 18202033 | COMPOSITIONS OF BERBERINE URSODEOXYCHOLATE AND METHODS THEREOF FOR TREATING PRIMARY SCLEROSING CHOLANGITIS | BARSKY, JARED | 15d |
| 18279931 | PHOTOCAGED CITRULLINE ANALOGS AND METHODS FOR SITE-SPECIFIC INCORPORATION OF CITRULLINE INTO PROTEINS | REYNOLDS, FRED H | 57d |
| 18904564 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | BRAUN, MADELINE E | — |
| 18805713 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | MCDOWELL, BRIAN E | — |
| 18837176 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | BARSKY, JARED | — |
| 18528393 | PROTEIN KINETIC ENSEMBLE PLATFORM FOR DISCOVERY OF BINDING POCKETS AND NOVEL LIGANDS | KRIANGCHAIVECH, KETTIP | — |
| 18280548 | METAP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | COPPINS, JANET L | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1618 | 2 |
| 1655 | 1 |
| 1658 | 1 |
| 1635 | 1 |
| 1629 | 1 |
| 1633 | 1 |
| 3791 | 1 |
| 1647 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18904564 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | Shenzhen Hightide Biopharmaceutical, Ltd. | BRAUN, MADELINE E | §102§112Other | Non-Final OA | — | Pending | Oct 02, 2024 | |
| 18805713 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. | MCDOWELL, BRIAN E | §112DP | Non-Final OA | — | Pending | Aug 15, 2024 | |
| 18837176 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | Xtalpi, Inc. | BARSKY, JARED | §112 | Non-Final OA | — | Pending | Aug 08, 2024 | |
| 18669853 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. | SHTERENGARTS, SAMANTHA L | §102§112DP | Non-Final OA | — | Pending | May 21, 2024 | |
| 18692308 | NEW COMBINATION DRUG FOR TREATING CORONAVIRUS INFECTIONS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Oneglobe Holdings Limited | BERRY, LAYLA D | §112 | Non-Final OA | — | Pending | May 13, 2024 | |
| 18528393 | PROTEIN KINETIC ENSEMBLE PLATFORM FOR DISCOVERY OF BINDING POCKETS AND NOVEL LIGANDS | Ensem Therapeutics, Inc. | KRIANGCHAIVECH, KETTIP | §101§102§112 | Non-Final OA | — | Pending | Dec 04, 2023 | |
| 18387769 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | Shenzhen Hightide Biopharmaceutical, Ltd. | BOECKELMAN, JACOB A | 1655 | §103§112Other | Final Rejection | 5d overdue | Pending | Nov 07, 2023 |
| 18280548 | METAP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | Canwell Biotech Limited | COPPINS, JANET L | 1628 | §112 | Non-Final OA | — | Pending | Sep 06, 2023 |
| 18279931 | PHOTOCAGED CITRULLINE ANALOGS AND METHODS FOR SITE-SPECIFIC INCORPORATION OF CITRULLINE INTO PROTEINS | UNIVERSITY OF MASSACHUSETTS | REYNOLDS, FRED H | 1658 | §102§103 | Final Rejection | 57d | Pending | Sep 01, 2023 |
| 18277846 | Novel Compositions for Conjugating Oligonucleotides and Carbohydrates | 1Globe Health Institute LLC | VANHORN, ABIGAIL LOUISE | 1635 | §103§112 | Non-Final OA | — | Pending | Aug 18, 2023 |
| 18272939 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Yanping Kong | GAUGER, PAUL RANDALL | 1629 | §112 | Final Rejection | — | Pending | Jul 18, 2023 |
| 18219656 | COMPOSITIONS AND METHODS OF DETECTING AND TREATING THROMBOSIS AND VASCULAR PLAQUES | Microvascular Therapeutics, LLC | VU, JAKE MINH | 1618 | §102§103Other | Final Rejection | 154d overdue | Pending | Jul 08, 2023 |
| 18208672 | PROTEIN-TEMPLATED SELF-ASSEMBLY OF A COVALENT POLYMER NETWORK FOR INTRACELLULAR TRAFFICKING AND TRACELESS RELEASE | UNIVERSITY OF MASSACHUSETTS | ROGERS, JAMES WILLIAM | 1618 | §112 | Final Rejection | 12d | Pending | Jun 12, 2023 |
| 18202033 | COMPOSITIONS OF BERBERINE URSODEOXYCHOLATE AND METHODS THEREOF FOR TREATING PRIMARY SCLEROSING CHOLANGITIS | Shenzhen Hightide Biopharmaceutical Ltd. | BARSKY, JARED | 1628 | §103Other | Final Rejection | 15d | Pending | May 25, 2023 |
| 18088544 | POLYMERIC NANOPARTICLES AND DERIVATIVES THEREOF FOR NUCLEIC ACID BINDING AND DELIVERY | UNIVERSITY OF MASSACHUSETTS | POPA, ILEANA | 1633 | §103Other | Final Rejection | 28d | Pending | Dec 24, 2022 |
| 18081604 | NANODEVICES AND METHODS FOR MEASURING BIOFLUIDIC FLOW USING A GRAPHENE-BASED MICROELECTRODE | UNIVERSITY OF MASSACHUSETTS | MONTGOMERY, MELISSA JO | 3791 | §102§103§112 | Non-Final OA | 9d | Pending | Dec 14, 2022 |
| 17777363 | COMPOSITIONS AND METHODS FOR OPTOGENETIC IMMUNOTHERAPY | UNIVERSITY OF MASSACHUSETTS | SUNSHINE, HANNAH LOUISE | 1647 | §102§103 | Non-Final OA | 5d overdue | Pending | May 17, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial